Alkermes (ALKS) Cash & Current Investments (2010 - 2026)
Alkermes' (ALKS) quarterly Cash & Current Investments came in at $656.6 million in Q2 2026, down 35.36% year-over-year from $1.0 billion in Q2 2025, and up 28.27% quarter-over-quarter from $511.9 million in Q1 2026.
Analysis
Alkermes (ALKS) Cash & Current Investments (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Cash & Current Investments for 17 consecutive years, with $656.6 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Cash & Current Investments fell 35.36% year-over-year to $656.6 million in Q2 2026; TTM through Jun 2026 was $656.6 million, a 35.36% decrease from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 48.97% from the prior year.
- Cash & Current Investments was $656.6 million for Q2 2026 at Alkermes, up from $511.9 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $1.1 billion in Q4 2025 and troughed at $511.9 million in Q1 2026.
- A 5-year average of $776.2 million and a median of $762.6 million in 2023 frame the typical range for Cash & Current Investments.
- Across the five-year window, Cash & Current Investments surged 53.25% in 2023 and plunged 42.1% in 2026, its largest moves.
- Over 5 years, Cash & Current Investments stood at $608.5 million in 2022, then rose by 27.12% to $773.5 million in 2023, then retreated by 2.82% to $751.7 million in 2024, then soared by 48.97% to $1.1 billion in 2025, then sank by 41.37% to $656.6 million in 2026.
- The last three Cash & Current Investments figures came in at $656.6 million (Q2 2026), $511.9 million (Q1 2026), and $1.1 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.32 Bn | 623.56 Bn | 17.26 Bn | 20.76 Bn |
| 2 | AbbVie | 440.60 Bn | 434.04 Bn | 12.70 Bn | 6.57 Bn |
| 3 | Merck | 365.39 Bn | 358.25 Bn | 12.21 Bn | 7.14 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | 7.69 Bn |
| 5 | Pfizer | 159.22 Bn | 147.52 Bn | 10.94 Bn | 11.70 Bn |
| 6 | Sanofi | 52.48 Bn | 45.10 Bn | 10.79 Bn | 7.38 Bn |
| 7 | Revolution Medicines | 44.21 Bn | 44.21 Bn | - | - |
| 8 | Incyte | 25.34 Bn | 20.81 Bn | 1.57 Bn | 4.54 Bn |
| 9 | United Therapeutics | 21.49 Bn | 18.82 Bn | 683.80 Mn | 2.66 Bn |
| 10 | Alkermes | 7.58 Bn | 6.93 Bn | 397.90 Mn | 656.58 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 656.58 Mn |
| Mar 31, 2026 | 511.86 Mn |
| Dec 31, 2025 | 1.12 Bn |
| Sep 30, 2025 | 1.11 Bn |
| Jun 30, 2025 | 1.02 Bn |
| Mar 31, 2025 | 884.02 Mn |
| Dec 31, 2024 | 751.67 Mn |
| Sep 30, 2024 | 908.86 Mn |
| Jun 30, 2024 | 876.12 Mn |
| Mar 31, 2024 | 745.05 Mn |
| Dec 31, 2023 | 773.49 Mn |
| Sep 30, 2023 | 889.15 Mn |
| Jun 30, 2023 | 829.05 Mn |
| Mar 31, 2023 | 600.46 Mn |
| Dec 31, 2022 | 608.47 Mn |
| Sep 30, 2022 | 580.18 Mn |
| Jun 30, 2022 | 580.97 Mn |
| Mar 31, 2022 | 528.87 Mn |
| Dec 31, 2021 | 536.31 Mn |
| Sep 30, 2021 | 560.30 Mn |